Patents by Inventor Mark Goulet

Mark Goulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5985901
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Feroze Ujjainwalla, Thomas F. Walsh, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Patent number: 5981550
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Thomas F. Walsh, Feroze Ujjainwalla, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Patent number: 5849764
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Lin Chu, Thomas F. Walsh, Michael H. Fisher, Narindar N. Girotra, Matthew J. Wyvratt, Peter Lin, Wallace T. Ashton
  • Patent number: 5780437
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Wallace T. Ashton, Lin Chu, Michael H. Fisher, Narindar N. Girotra, Peter Lin, Matthew J. Wyvratt
  • Patent number: 5756507
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Lin Chu, Wallace T. Ashton, Michael H. Fisher, Matthew J. Wyvratt, Roy G. Smith, Robert L. Bugianesi, Mitree M. Ponpipom, Yi Tien Yang, Peter Lin
  • Patent number: 5693648
    Abstract: Substituted compounds of the FK-506 Type. These compounds are useful for the same or essentially the same purposes as FK-506 and are applied in the same or a similar manner. These compounds are immunosuppressants and useful for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. Still other uses are described in the disclosure.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: December 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Helen M. Organ, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5565560
    Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: October 4, 1993
    Date of Patent: October 15, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Helen M. Organ, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5532248
    Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: July 2, 1996
    Assignee: Merck Co., Inc.
    Inventors: Mark Goulet, William H. Parsons, Helen M. Organ, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5349061
    Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: September 20, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Sinclair, Joung Goulet, Frederick Wong, Mark Goulet, William H. Parsons, Matthew J. Wyvratt
  • Patent number: 5344925
    Abstract: Imidazolidyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: September 6, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5310903
    Abstract: Imidazolidyl rapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, William H. Parsons, Matthew J. Wyvratt
  • Patent number: 5258389
    Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.
    Type: Grant
    Filed: November 9, 1992
    Date of Patent: November 2, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5252732
    Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: August 5, 1992
    Date of Patent: October 12, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Sinclair, Joung Goulet, Frederick Wong, Mark Goulet, William H. Parsons, Matthew J. Wyvratt
  • Patent number: 5250678
    Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.
    Type: Grant
    Filed: May 1, 1992
    Date of Patent: October 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Frederick Wong, Peter J. Sinclair, Matthew J. Wyvratt
  • Patent number: 5247076
    Abstract: Imidazolidyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
    Type: Grant
    Filed: August 4, 1992
    Date of Patent: September 21, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
  • Patent number: 5208228
    Abstract: Aminomacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by incorporation of a nitrogen substituent at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma.
    Type: Grant
    Filed: May 13, 1991
    Date of Patent: May 4, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Hyun O. Ok, Thomas R. Beattie, Michael H. Fisher, Matthew J. Wyvratt, Mark Goulet
  • Patent number: 5189042
    Abstract: Fluoromacrolides and derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by oxidation and fluorination at C-20. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma. Furthermore, these macrolides are useful as hair revitalizing agents, especially in the treatment of male pattern alopecia or alopecia senilis.
    Type: Grant
    Filed: August 22, 1991
    Date of Patent: February 23, 1993
    Assignee: Merck & Co. Inc.
    Inventors: Mark Goulet, Thomas R. Beattie, Matthew J. Wyvratt
  • Patent number: 5162334
    Abstract: Amino O-alkyl, O-alkenyl and O-alkynylmacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and amination at C-3"/C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma.
    Type: Grant
    Filed: May 13, 1991
    Date of Patent: November 10, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Matthew J. Wyvratt
  • Patent number: 5147877
    Abstract: Macrolides of the general structural Formula I: ##STR1## have been prepared. These macrolides are antagonists of FK-506-type immunosuppressants and are useful for modifying dosages of FK-506-type immunosuppressants in the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. Furthermore, the compounds of the present invention may have utility as antidotes for overdoses of FK-506-type immunosuppressants. In addition, these macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants.
    Type: Grant
    Filed: September 12, 1991
    Date of Patent: September 15, 1992
    Assignee: Merck & Co. Inc.
    Inventor: Mark Goulet